Learning How to Manage Immunotherapy or TKI-Related AEs in Advanced RCC
Clinicians are learning how to identify adverse effects relating to either immunotherapy or tyrosine kinase inhibitors for patients with advanced renal cell carcinoma.
A Multifaceted Approach to Optimizing Treatment in RCC
Moshe Ornstein, MD, discusses the heterogeneous population that comprise patients with advanced renal cell carcinoma.
Evolving Treatment Landscape of RCC: Future Directions in Care
Closing out their program on renal cell carcinoma management, key opinion leaders share closing thoughts on emerging therapies and how the field is evolving.
Frontline IO-Based Regimens in Sarcomatoid or Rhabdoid Metastatic nccRCC
Centering discussion on sarcomatoid and rhabdoid non-clear cell renal cell carcinoma, panelists consider frontline IO-based regimens and their value in this setting.
Chromophobe RCC and Papillary Kidney Cancer: Novel Treatment Strategies
A brief discussion centered on optimal treatment strategies for patients with chromophobe or papillary kidney cancers.
Non-Clear Cell Renal Cell Carcinoma: Interpreting Data With IO/TKI Combination Therapies
Key opinion leaders in the field of renal cell carcinoma management reflect on recent data with IO/TKI combination therapy in patients with non-clear cell disease.
Updates from ASCO 2023: KEYNOTE-B61 Study in Non-Clear Cell Renal Cell Carcinoma
Switching its focus to non-clear cell RCC, the panel reviews data presented at ASCO 2023 on KEYNOTE-B61, combining lenvatinib + pembrolizumab in this setting.
Factors Aiding in the Selection of Frontline Therapy in Advanced Clear Cell RCC
Panelists shed light on key factors that help to inform the selection of frontline therapy in patients with advanced clear cell renal cell carcinoma.
Selecting Frontline Therapy for Patients With Advanced Clear Cell RCC
In the context of the available frontline treatment armamentarium for advanced clear cell RCC, key opinion leaders consider how they would select or sequence therapy.
Advanced Clear Cell RCC: Impact of the CLEAR Trial on Real-World Practice
Expert panelists consider how updated data from the CLEAR trial of lenvatinib + pembrolizumab in advanced clear cell RCC have impacted their real-world clinical practice.
Data From KCRS 2023: The CLEAR and TRAVERSE Studies in Advanced Clear Cell RCC
Centering discussion on the KCRS 2023 annual meeting, experts in renal cell carcinoma elucidate data from the CLEAR and TRAVERSE studies in clear cell disease.
Cabozantinib Plus Nivolumab and Ipilimumab for Advanced Non-Clear Cell RCC
Experts discuss recent data on a triplet combination therapy for patients with advanced non-clear cell renal cell carcinoma.
Recent Data Updates in the Treatment of Non-Clear Cell RCC
Drs Robert Motzer and Moshe Ornstein discuss the results of the KEYNOTE-B61 study in patients with non-clear cell renal cell carcinoma.
Emerging Advancements in the Treatment of Clear Cell RCC
The panel highlights novel agents under investigation for the treatment of clear cell renal cell carcinoma.
Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Metastatic RCC
Moshe Ornstein, MD, reviews the design and efficacy and safety data from the phase 3 CONTACT-03 study in metastatic renal cell carcinoma.
Managing Adverse Events in Patients With Advanced RCC Receiving an IO/TKI Combination Regimen
Dr Moshe Ornstein details the adverse events seen with IO/TKI combination regimens in patients with advanced renal cell carcinoma and the best strategies for management.
Treating Patients With Metastasized RCC
Experts discuss the optimal treatment of patients with renal cell carcinoma and brain, bone, or lung metastases.
Selecting an Appropriate Frontline Treatment Regimen for Patients With Advanced RCC
Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.
Comparing IO/TKI and IO/IO First-Line Treatment Regimens in Advanced RCC
Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.
Pembrolizumab Plus Axitinib Versus Sunitinib for First-Line Treatment of Advanced Clear Cell RCC
Brian Rini, MD, reviews data from the 5-year analysis of the KEYNOTE-426 trial in advanced clear cell renal cell carcinoma.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma (aRCC)
Robert Motzer, MD, presents the overall survival analysis data from the 4-year follow-up of the CLEAR study in patients with advanced renal cell carcinoma.
Frontline Therapy for Non-Clear Cell RCC
The panel wraps up their discussion with a review of how they would approach treating frontline non-clear cell RCC.
Disease Progression After Adjuvant Pembrolizumab Therapy for RCC
The panel shares how they would treat a patient with advanced RCC after disease progression on adjuvant pembrolizumab.
Clinical Trials in Adjuvant IO Therapy for RCC
Tian Zhang, MD, explains whether recent data from ESMO 2022 has changed their approach to adjuvant immune therapy in advanced RCC.
Phase III Trial of Lenvatinib, Pembrolizumab, and Belzutifan or Quavonlimab in Frontline Advanced RCC
The panel continues their discussion of investigational triplet therapies in frontline RCC treatment.
COSMIC-313 Trial of Cabozantinib, Nivolumab and Ipilimumab in Frontline Advanced RCC
The doctors review data from the COSMIC-313 trial investigating a frontline triplet therapy for advanced RCC.
Approaches to Dosing TKIs in Patients with Advanced RCC
Best approaches to dosing and dose-reduction of TKI agents in the treatment of advanced RCC.
Switching a Patient with Advanced RCC Between IO + TKI and IO + IO Combination Regimens
The panel discusses which patients they would consider switching between immunotherapy combination treatments.
Approaches to the Frontline Treatment of Advanced Kidney Cancer
Experts summarize their most common frontline treatment approaches to advanced RCC.
Observing Patients with Advanced Renal Cell Carcinoma Before Systemic Therapy
Moshe Ornstein, MD, explains which patients with RCC he observes for progression prior to systemic therapy.